LEXINGTON, Mass., Apr 21, 2010 (BUSINESS WIRE) –AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report
unaudited consolidated financial results for the quarter ended March 31,
2010 after the U.S. financial markets close on April 27, 2010. The
announcement will be followed by a conference call and webcast with
slides at 4:30 p.m. ET during which management will discuss the
Company’s financial results, business highlights, commercial progress
and development programs.
To access the conference call via telephone, please dial (877) 412-6083
from the United States or (702) 495-1202 for international access. A
telephone replay will be available from approximately 6:30 p.m. ET on
April 27, 2010 through midnight April 29, 2010. To access a replay of
the conference call, dial (800) 642-1687 from the United States or (706)
645-9291 for international access. The passcode for the live call and
the replay is 70132254.
The call will be webcast with slides and accessible through the
Investors section of the Company’s website at www.amagpharma.com.
The webcast replay will be available from approximately 6:30p.m.
ET on April 27, 2010 through midnight May 27, 2010.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease. On June 30, 2009, AMAG received approval from the U.S. Food and
Drug Administration to market Feraheme(R) (ferumoxytol)
Injection for intravenous (IV) use for the treatment of iron deficiency
anemia in adult chronic kidney disease patients. For additional company
and product information, please visit www.amagpharma.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
SOURCE: AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals
Carol Miceli, 617-498-3361
